Tags

Type your tag names separated by a space and hit enter

Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function.
Exp Dermatol. 2018 12; 27(12):1378-1387.ED

Abstract

BACKGROUND

Rosacea is a chronic inflammatory skin disease. Characteristic vascular changes in rosacea skin include enlarged, dilated vessels of the upper dermis and blood flow increase. Brimonidine is approved for symptomatic relief of the erythema of rosacea. It acts by selectively binding to α2-adrenergic receptors present on smooth muscle in the peripheral vasculature, resulting in transient local vasoconstriction.

OBJECTIVES

To provide further evidence of the anti-inflammatory potential of brimonidine across preclinical models of skin inflammation and its ability to decrease the neutrophil infiltration in human skin after ultraviolet light exposure.

METHODS

The anti-inflammatory properties of brimonidine through modulation of the vascular barrier function were assessed using in vivo neurogenic vasodilation and acute inflammatory models and a well-described in vitro transmigration assay. A clinical study assessed the neutrophil infiltration in human skin after exposure to UV in 37 healthy Caucasian male subjects.

RESULTS

In vitro, brimonidine affects the transmigration of human neutrophils through the endothelial barrier by modulating adhesion molecules. In vivo, in the mouse, topical treatment with brimonidine, used at a vasoconstrictive dose, confirmed its anti-inflammatory properties and prevented leucocyte recruitment (rolling and adhesion) mediated by endothelial cells. Topical pretreatment with brimonidine tartrate 0.33% gel once a day for 4 days significantly prevented neutrophil infiltration by 53.9% in human skin after exposure to UV light.

CONCLUSION

Results from in vitro, in vivo and from a clinical study indicate that brimonidine impacts acute inflammation of the skin by interfering with neurogenic activation and/or recruitment of neutrophils.

Authors+Show Affiliations

GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.GALDERMA R&D-Nestlé Skin Health, Sophia Antipolis, France.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30290018

Citation

Bertino, Béatrice, et al. "Brimonidine Displays Anti-inflammatory Properties in the Skin Through the Modulation of the Vascular Barrier Function." Experimental Dermatology, vol. 27, no. 12, 2018, pp. 1378-1387.
Bertino B, Blanchet-Réthoré S, Thibaut de Ménonville S, et al. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Exp Dermatol. 2018;27(12):1378-1387.
Bertino, B., Blanchet-Réthoré, S., Thibaut de Ménonville, S., Reynier, P., Méhul, B., Bogouch, A., Gamboa, B., Dugaret, A. S., Zugaj, D., Petit, L., Roquet, M., Piwnica, D., Vial, E., Bourdès, V., Voegel, J. J., & Nonne, C. (2018). Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Experimental Dermatology, 27(12), 1378-1387. https://doi.org/10.1111/exd.13793
Bertino B, et al. Brimonidine Displays Anti-inflammatory Properties in the Skin Through the Modulation of the Vascular Barrier Function. Exp Dermatol. 2018;27(12):1378-1387. PubMed PMID: 30290018.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. AU - Bertino,Béatrice, AU - Blanchet-Réthoré,Sandrine, AU - Thibaut de Ménonville,Séverine, AU - Reynier,Philippe, AU - Méhul,Bruno, AU - Bogouch,Audrey, AU - Gamboa,Bastien, AU - Dugaret,Anne Sophie, AU - Zugaj,Didier, AU - Petit,Laurent, AU - Roquet,Manon, AU - Piwnica,David, AU - Vial,Emmanuel, AU - Bourdès,Valerie, AU - Voegel,Johannes J, AU - Nonne,Christelle, PY - 2018/07/04/received PY - 2018/10/01/accepted PY - 2018/10/6/pubmed PY - 2019/10/23/medline PY - 2018/10/6/entrez KW - Erythema KW - leucocyte recruitment KW - rosacea KW - transmigration of neutrophils KW - vasoconstriction SP - 1378 EP - 1387 JF - Experimental dermatology JO - Exp Dermatol VL - 27 IS - 12 N2 - BACKGROUND: Rosacea is a chronic inflammatory skin disease. Characteristic vascular changes in rosacea skin include enlarged, dilated vessels of the upper dermis and blood flow increase. Brimonidine is approved for symptomatic relief of the erythema of rosacea. It acts by selectively binding to α2-adrenergic receptors present on smooth muscle in the peripheral vasculature, resulting in transient local vasoconstriction. OBJECTIVES: To provide further evidence of the anti-inflammatory potential of brimonidine across preclinical models of skin inflammation and its ability to decrease the neutrophil infiltration in human skin after ultraviolet light exposure. METHODS: The anti-inflammatory properties of brimonidine through modulation of the vascular barrier function were assessed using in vivo neurogenic vasodilation and acute inflammatory models and a well-described in vitro transmigration assay. A clinical study assessed the neutrophil infiltration in human skin after exposure to UV in 37 healthy Caucasian male subjects. RESULTS: In vitro, brimonidine affects the transmigration of human neutrophils through the endothelial barrier by modulating adhesion molecules. In vivo, in the mouse, topical treatment with brimonidine, used at a vasoconstrictive dose, confirmed its anti-inflammatory properties and prevented leucocyte recruitment (rolling and adhesion) mediated by endothelial cells. Topical pretreatment with brimonidine tartrate 0.33% gel once a day for 4 days significantly prevented neutrophil infiltration by 53.9% in human skin after exposure to UV light. CONCLUSION: Results from in vitro, in vivo and from a clinical study indicate that brimonidine impacts acute inflammation of the skin by interfering with neurogenic activation and/or recruitment of neutrophils. SN - 1600-0625 UR - https://www.unboundmedicine.com/medline/citation/30290018/Brimonidine_displays_anti_inflammatory_properties_in_the_skin_through_the_modulation_of_the_vascular_barrier_function_ DB - PRIME DP - Unbound Medicine ER -